Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate UpdateAugust 5, 2021
Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development OfficerAugust 2, 2021
Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical StudyJuly 13, 2021
Press Release History
Resmetirom is an investigational therapy and has not been approved by the FDA (or any other regulatory authority). Resmetirom
is only available for use in a clinical trial setting (ClinicalTrials.gov NCT03900429 and NCT04197479)
Website Developed by Alan Leff Associates, Inc.